This HTML5 document contains 45 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n17http://linked.opendata.cz/resource/drugbank/drug/DB06712/identifier/wikipedia/
n16http://linked.opendata.cz/resource/drugbank/drug/DB06712/identifier/pharmgkb/
n13http://linked.opendata.cz/resource/drugbank/drug/DB06712/identifier/bindingdb/
n14http://linked.opendata.cz/resource/drugbank/drug/DB06712/identifier/pubchem-compound/
n12http://linked.opendata.cz/resource/drugbank/drug/DB06712/identifier/kegg-drug/
n15http://linked.opendata.cz/resource/drugbank/drug/DB06712/identifier/pubchem-substance/
n6http://bio2rdf.org/drugbank:
n11http://linked.opendata.cz/resource/drugbank/drug/DB06712/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n18http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n8http://linked.opendata.cz/resource/atc/
n7http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB06712
rdf:type
n3:Drug
n3:description
Nilvadipine is a calcium channel blocker (CCB) for treatment of hypertension.
n3:group
approved
n3:indication
For the management of vasospastic angina, chronic stable angina and hypertension.
owl:sameAs
n6:DB06712 n18:DB06712
dcterms:title
Nilvadipine
adms:identifier
n11:DB06712 n12:D01908 n13:50017328 n14:4494 n15:99443264 n16:PA165958385 n17:Nilvadipine
n3:mechanismOfAction
Nilvadipine inhibits the influx of extracellular calcium through myocardial and vascular membrane pores by physically plugging the channel. The decrease in intracellular calcium inhibits the contractile processes of smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
n3:synonym
Nivadil
n3:foodInteraction
Take without regard to meals
n3:synthesisReference
Minoru Nakano, Toshinobu Uemura, Shinichi Morizane, Kiyoshi Okuda, Keiko Nakata, "Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine." U.S. Patent US5340591, issued March, 1985.
n3:IUPAC-Name
n4:271B509B-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B50A1-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B50A0-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B509D-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B509E-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B509F-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5099-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B509A-363D-11E5-9242-09173F13E4C5 n4:271B5097-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5098-363D-11E5-9242-09173F13E4C5
n7:hasATCCode
n8:C08CA10
n3:H-Bond-Acceptor-Count
n4:271B50A7-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B50A8-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B50A2-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B50A3-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B50A5-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B50A4-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B50A6-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
75530-68-6
n3:Bioavailability
n4:271B50AC-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B50AE-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B50AF-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B50AB-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B50AA-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B50AD-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B509C-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B50A9-363D-11E5-9242-09173F13E4C5